These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 12001473)

  • 1. [HER-2/neu oncogene in the selection of treatment for breast cancer and as a target of immunotherapy].
    Isola J; Järvinen T; Tanner M; Holli K
    Duodecim; 2000; 116(15):1538-46. PubMed ID: 12001473
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside.
    Hanna W; Kahn HJ; Trudeau M
    Mod Pathol; 1999 Aug; 12(8):827-34. PubMed ID: 10463486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
    Emens LA
    Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.
    Gonzalez-Angulo AM; Hortobágyi GN; Esteva FJ
    Oncologist; 2006 Sep; 11(8):857-67. PubMed ID: 16951389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Breast cancer].
    Tokuda Y; Saito Y; Suzuki Y; Ohta M; Tajima T
    Nihon Rinsho; 2002 Mar; 60(3):563-9. PubMed ID: 11904974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects and costs of adjuvant chemotherapy for operable lymph node positive breast cancer with HER2/neu overexpression].
    Bult P; Tjan-Heijnen VC; van Krieken H
    Ned Tijdschr Geneeskd; 2006 Jul; 150(26):1481; author reply 1481-3. PubMed ID: 16875274
    [No Abstract]   [Full Text] [Related]  

  • 7. [New antibody for breast cancer therapy. Interview by Brigitte Schalhorn].
    Eiermann W
    Fortschr Med; 1998 Jun; 116(18-19):18. PubMed ID: 9691532
    [No Abstract]   [Full Text] [Related]  

  • 8. [Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene?].
    Beuzeboc P; Scholl S; Garau XS; Vincent-Salomon A; Cremoux PD; Couturier J; Palangié T; Pouillart P
    Bull Cancer; 1999 Jun; 86(6):544-9. PubMed ID: 10417428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
    Paik S; Kim C; Wolmark N
    N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeted therapy for cancer: the HER-2/neu and Herceptin story.
    Ross JS; Gray GS
    Clin Leadersh Manag Rev; 2003; 17(6):333-40. PubMed ID: 14692077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Herceptin (trastuzamab) in advanced breast cancer.
    Stebbing J; Copson E; O'Reilly S
    Cancer Treat Rev; 2000 Aug; 26(4):287-90. PubMed ID: 10913383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer?
    Seidman AD
    Nat Clin Pract Oncol; 2006 Apr; 3(4):178-9. PubMed ID: 16596138
    [No Abstract]   [Full Text] [Related]  

  • 13. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
    Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
    Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [DCIS and HER2/neu].
    Tulusan AH
    Onkologie; 2002 Dec; 25 Suppl 5():11-2; discussion 13. PubMed ID: 23573612
    [No Abstract]   [Full Text] [Related]  

  • 15. [Relationship between overexpression of HER-2/neu protein and prognosis in epithelial ovarian cancer].
    Sasaki N; Takano M; Kudou K; Kita T; Kikuchi Y
    Nihon Rinsho; 2004 Oct; 62 Suppl 10():582-6. PubMed ID: 15535312
    [No Abstract]   [Full Text] [Related]  

  • 16. HER-2/neu expression in primary and metastatic breast cancer.
    Lower EE; Glass E; Blau R; Harman S
    Breast Cancer Res Treat; 2009 Jan; 113(2):301-6. PubMed ID: 18273700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
    Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
    Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controversies in the use of adjuvant trastuzumab (Herceptin).
    Chowdhury S; Pickering L; Ellis P
    J Br Menopause Soc; 2006 Dec; 12(4):172-4. PubMed ID: 17178019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer.
    Kubo M; Morisaki T; Kuroki H; Tasaki A; Yamanaka N; Matsumoto K; Nakamura K; Onishi H; Baba E; Katano M
    Anticancer Res; 2003; 23(6a):4443-9. PubMed ID: 14666732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [HER-2 diagnostics].
    Bánkfalvi A
    Magy Onkol; 2002; 46(1):11-5. PubMed ID: 12050677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.